2017. Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s12. DOI:https://doi.org/10.25251/skin.1.supp.11.